Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. (AORT) insider transaction: the VP, Chief Accounting Officer reported a sale of 1,789 shares of common stock on 11/10/2025 at $44.619 per share. Following the transaction, the reporting person beneficially owns 144,862 shares, held directly.
The filing states the shares were sold to cover taxes due upon the vesting of restricted stock units, described as a “sell to cover” and not a discretionary trade.
Artivion, Inc. (AORT) disclosed an insider transaction by its SVP, Clinical & MD Affairs. On 11/10/2025, the officer sold 2,566 shares of common stock at $44.619 per share. The filing states the shares were sold upon the vesting of restricted stock units to cover tax withholding, described as a “sell to cover” and not a discretionary trade.
Following the transaction, the officer directly beneficially owned 61,634 shares. The report was filed as a single‑person Form 4 submission.
AORT received a Rule 144 notice for a proposed sale of 2,566 common shares through Fidelity Brokerage Services, with an aggregate market value of $114,492.10. The approximate sale date is 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. A separate table shows a sale of 18,200 shares on 08/27/2025 by Marshall S. Stanton, for $801,211.32 in gross proceeds. Shares outstanding were 47,374,939.
AORT: An affiliate filed a Form 144 notice to sell up to 17,580 shares of common stock, reflecting an aggregate market value of $784,400.26. The filing lists an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. The filer also reported sales in the past three months: 12,500 shares on 08/15/2025 for gross proceeds of $528,991.00. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being sold.
Artivion (AORT) received a Form 144 notice from a shareholder for a proposed sale of 10,000 common shares with an aggregate market value of $461,800. The filing lists an approximate sale date of 11/11/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities to be sold were acquired from the issuer via an option granted on 11/08/2022, with acquisition and cash payment dated 11/11/2025. Shares outstanding were 47,374,939.
The filer reported prior sales in the last three months: 23,356 shares on 08/12/2025 for $1,004,605.97 and 10,000 shares on 08/25/2025 for $443,700.00.
Form 144 notice of proposed sale: A shareholder filed to sell up to 2,960 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $132,071.94. The filing lists an approximate sale date of 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, in an amount of 2,960 shares, treated as compensation. Shares outstanding were 47,374,939 at the time referenced in the form; this is a baseline figure, not the amount being sold.
The person for whose account the securities are to be sold reported prior sales in the past three months: 23,356 shares on 08/12/2025 for gross proceeds of $1,004,605.97, and 10,000 shares on 08/25/2025 for gross proceeds of $443,700.00.
Artivion (AORT) received a Form 144 notice indicating a planned sale of up to 1,789 shares of common stock. The filing lists an aggregate market value of $79,823.21 and an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The seller acquired these shares on 11/07/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 47,374,939, providing scale relative to the proposed sale.
Artivion (AORT): Notice of proposed sale under Rule 144. A filing indicates an intent to sell 3,373 common shares, with an approximate sale date of 11/10/2025. The filing lists an aggregate market value of $150,499.55, with trading on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, recorded as compensation. As context, 47,374,939 shares were outstanding. In the past three months, the named seller reported a sale of 10,802 shares on 08/12/2025 for $471,752.51.
This is an administrative notice of a potential sale under Rule 144 and does not itself execute a transaction.
Morgan Stanley filed Schedule 13G/A (Amendment No. 2) reporting beneficial ownership of 2,074,975 shares of Artivion, Inc. (AORT) common stock, representing 4.4% of the class as of the reporting event dated 09/30/2025. The filing states Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class.
The filing lists shared voting power: 208,344 shares and shared dispositive power: 2,074,975 shares, with 0 shares under sole voting or dispositive power. The certification indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) reported third‑quarter 2025 results with total revenues of $113.4 million, up 18% year over year. Medical devices drove growth, led by aortic stent grafts $39.6 million (+38%) and On‑X $26.8 million (+25%), while preservation services contributed $25.7 million (+5%). Gross margin was $74.4 million, and operating income rose to $12.5 million.
Net income was $6.5 million (diluted EPS $0.13) versus a loss a year ago, aided by a $3.5 million PerClot sales milestone gain. Operating cash flow reached $20.3 million year to date, ending cash was $73.4 million. The company eliminated its $100.0 million Convertible Senior Notes via exchanges into ~4.35 million shares and small residual settlement, reducing interest expense. A credit amendment extended maturities to January 18, 2031 and lowered interest margins; total principal debt stood at $220.0 million with long‑term debt (net) of $214.9 million. Shares outstanding were 47,374,939 as of October 31, 2025.